AARA News
Switching from Adalimumab Reference Product to and Among Adalimumab Biosimilars Outside the USA: Insights for US Clinicians
A new review article led by Dr. John R. P. Tesser, MD, FACP, FACR, MACR, and AARA Clinical Research offers key insights for U.S. clinicians on switching from reference product adalimumab to its biosimilars based on data from outside the U.S. The review finds that switching to adalimumab biosimilars is generally safe and effective across multiple chronic inflammatory diseases. While most patients maintain stable outcomes after switching, the study highlights the importance of patient education, physician guidance, and supportive policies. The findings support broader use of biosimilars to reduce costs and expand access to care in the U.S. healthcare system.
Read the full review article here:
https://link.springer.com/article/10.1007/s40259-025-00719-z
AARA Hits the Hill!
Pictured from left to right: AARA Executive Leadership members Dr. Andrew Sharobeem, CEO Angel Magar, and Dr. Nehad Soloman stand in front of Capitol Hill.
We are proud to stand with the American College of Rheumatology on Capitol Hill—advocating for our patients, supporting fellow rheumatologists in delivering exceptional care, opposing Medicaid cuts, demanding meaningful Pharmacy Benefit Manager reform, and fighting for better resources for our veterans. We’re here for Arizona—and for patients across the nation!
Andrew Sharobeem, DO, FACR
EULAR 2025 Congress Recognizes Dr. Tesser and AARA Clinical Research with Abstract Award, New RA Treatment on the Horizon
The European Alliance of Associations for Rheumatology (EULAR) has awarded Dr. John R. P. Tesser, MD, FACP, FACR, MACR, and AARA Clinical Research with an Abstract Award in the category of Clinical Research.
The seminal abstract recognized with this achievement summarizes the test of a potential new treatment for rheumatoid arthritis (RA) that utilizes an implantable device to stimulate the vagus nerve with the goal of reducing inflammation and joint pain for participants whose RA has not improved with traditional medications—bDMARDs and tsDMARDs.
Tracking the improvement of RA symptoms by at least 20% (ACR20), results from the double-blind study proved statistically significant with 35.2% of participants in the treatment group reaching the desired endpoint versus 24.2% of participants in the control group after 12 weeks. Rates of improvement for participants with only one prior exposure to bDMARDs was nearly double that of the control group at 44.2%.
Click here to learn more about the study and its pivotal impact on the future treatment of RA!
AARA Avondale Grand Opening Marks Greater Access to Care
On February 12th, 2025, the City of Avondale welcomed AARA and Phoenix Heart to the greater West Valley community at the grand opening of their brand-new, state-of-the-art medical facilities on Rancho Santa Fe Boulevard.
Dr. Andrew Sharobeem, Partner Rheumatologist of AARA, joined Dr. Reshmaal Gomes, Cardiologist of Phoenix Heart, in a joint ribbon-cutting ceremony commemorating their partnership and dedication to serving the growing needs of the West Valley community.
AARA CEO, Angel Magar, joined Dr. Sharobeem and other leadership members in front of AARA’s new, modern space for a practice-specific ceremony. The team bristled with excitement as the new Avondale office (formerly Phoenix) offers expanded exam and infusion areas, as well as advanced technology to support enhanced patient care.
Other helpful links:
City of Avondale
Phoenix Heart
